Looking Ahead: TAR-200's Evolving Role in NMIBC and Future Directions in Bladder Cancer Care

Christopher Cutie, MD, of Johnson & Johnson Innovative Medicine, shares his thoughts on the potential of TAR-200 to redefine care for BCG-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC). Designed as a bladder-preserving alternative for patients unfit or unwilling to undergo radical cystectomy, TAR-200 integrates seamlessly into urologic practices, offering logistical advantages and accessibility for older populations. In this video, Dr. Cutie highlights its innovative approach, including synergy with systemic checkpoint inhibitors and future possibilities with advanced therapies like antibody-drug conjugates and radioligands.